Bristol-Myers Squibb GmbH & Co. KGaA
European Commission Approves Labelling Update for REYATAZ® (atazanavir sulfate) in Pregnant Women Living With HIV
Paris, November 25 (ots/PRNewswire) - - REYATAZ(R) is the only boosted PI to include dosing and medical guidance in pregnancy and postpartum in the label - Bristol-Myers Squibb Company today announced that the European Commission approved a labelling update for REYATAZ(R) (atazanavir sulfate) based on new data ...